International Urology and Nephrology

, Volume 50, Issue 10, pp 1765–1770 | Cite as

Prophylactic selective arterial embolization for renal angiomyolipomas: efficacy and evaluation of predictive factors of significant shrinkage

  • Letao Lin
  • Chengen Wang
  • Renguang Pei
  • Haitao Guan
  • Jian Wang
  • Min Yang
  • Xiaoqiang Tong
  • Yinghua ZouEmail author
Urology - Original Paper



To evaluate the efficacy of prophylactic selective arterial embolization (SAE) of angiomyolipomas (AMLs) and to find out predictive factors of significant shrinkage of AMLs after SAE.


Patients receiving prophylactic SAE for renal AMLs with complete medical records were included. The changes of the size, urine erythrocyte counts, and serum creatinine of all patients pre- and post-embolization were assessed. Demographic data, symptoms, the background of tuberous sclerosis complex (TSC), aneurysms, enhancement features, initial tumor sizes, and serum creatinine pre-embolization were estimated as predictive factors of significant shrinkage in size.


Forty-five patients receiving prophylactic SAE for AMLs successfully in our center were included with median follow-up of 14.0 months (interquartile range 6.5–40.5). Mean size of AMLs decreased from 10.7 ± 6.2 to 8.3 ± 5.9 cm by 23.4% ± 20.6% at the latest follow-up (P < 0.001). Urine erythrocytes decreased significantly after SAE (11.1 [interquartile range 5.7–23.2] vs. 6.4 [interquartile range 2.7–13.4], P < 0.001). In addition, there was no significant change between the serum creatinine before and after embolization (81.8 ± 14.9 mmol/L vs. 83.6 ± 17.1 mmol/L, P = 0.224). Of the variables mentioned above, only the enhanced area of AMLs before SAE was statistically significant between the groups with and without significant shrinkage (P < 0.001). In multiv-ariate analysis, enhanced area < 25% (AOR = 0.015, 95% CI 0.001–0.367) and having the background of TSC (AOR = 0.056, 95% CI 0.004–0.799) were identified as predictive factors of significant shrinkage of the tumors.


Prophylactic SAE is effective in reducing the size of renal AMLs and decreasing urine erythrocytes with preservation of renal function. Significant shrinkage of AMLs after SAE is modulated by the enhanced area and the background of TSC.


Angiomyolipoma Selective arterial embolization Kidney neoplasms Tuberous sclerosis 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

For this retrospective study, formal consent is not required.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Steiner MS, Goldman SM, Fishman EK, Marshall FF (1993) The natural history of renal angiomyolipoma. J Urol 150:1782–1786CrossRefPubMedGoogle Scholar
  2. 2.
    Kontos S, Politis V, Fokitis I, Lefakis G, Koritsiadis G, Simaioforidis V, Kachrilas S, Chatziplis E, Koritsiadis S (2008) Rapture of renal angiomyolipoma during pregnancy: a case report. Cases J 1:245. CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Konosu-Fukaya S, Nakamura Y, Fujishima F, Kasajima A, Takahashi Y, Joh K, Ikeda Y, Ioritani N, Watanabe M, Sasano H (2013) Bilateral papillary renal cell carcinoma and angiomyolipoma in the patients with autosomal dominant polycystic kidney disease: case report of two cases and literature review. Pol J Pathol 64:303–307CrossRefPubMedGoogle Scholar
  4. 4.
    Radhakrishnan R, Verma S (2011) Clinically relevant imaging in tuberous sclerosis. J Clin Imaging Sci 1:39. CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Murray TE, Doyle F, Lee M (2015) Transarterial embolization of angiomyolipoma: a systematic review. J Urol 194:635–639. CrossRefPubMedGoogle Scholar
  6. 6.
    Sun P, Liu J, Charles H, Hulbert J, Bissler J (2017) Outcomes of angioembolization and nephrectomy for renal angiomyolipoma associated with tuberous sclerosis complex: a real-world US national study. Curr Med Res Opin 33:821–827. CrossRefPubMedGoogle Scholar
  7. 7.
    Kato H, Kuwatsuru R, Inoue T, Okada S, Aida M, Yamashiro Y (2018) Superselective transcatheter arterial embolization for large unruptured renal angiomyolipoma in lymphangioleiomyomatosis. J Vasc Interv Radiol. CrossRefPubMedGoogle Scholar
  8. 8.
    Hocquelet A, Cornelis F, Le Bras Y, Meyer M, Tricaud E, Lasserre AS, Ferriere JM, Robert G, Grenier N (2014) Long-term results of preventive embolization of renal angiomyolipomas: evaluation of predictive factors of volume decrease. Eur Radiol 24:1785–1793. CrossRefPubMedGoogle Scholar
  9. 9.
    Han YM, Kim JK, Roh BS, Song HY, Lee JM, Lee YH, Lee SY, Chung GH, Kim CS, Sohn MH, Choi KC (1997) Renal angiomyolipoma: selective arterial embolization–effectiveness and changes in angiomyogenic components in long-term follow-up. Radiology 204:65–70. CrossRefPubMedGoogle Scholar
  10. 10.
    Ramon J, Rimon U, Garniek A, Golan G, Bensaid P, Kitrey ND, Nadu A, Dotan ZA (2009) Renal angiomyolipoma: long-term results following selective arterial embolization. Eur Urol 55:1155–1161. CrossRefPubMedGoogle Scholar
  11. 11.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. CrossRefPubMedGoogle Scholar
  12. 12.
    Diaz DLA, Pedrosa I (2017) Imaging and screening of kidney cancer. Radiol Clin North Am 55:1235–1250. CrossRefGoogle Scholar
  13. 13.
    Kiefer RM, Stavropoulos SW (2017) The role of interventional radiology techniques in the management of renal angiomyolipomas. Curr Urol Rep 18:36. CrossRefPubMedGoogle Scholar
  14. 14.
    Wang C, Yang M, Tong X, Wang J, Guan H, Niu G, Yan Z, Zhang B, Zou Y (2017) Transarterial embolization for renal angiomyolipomas: a single centre experience in 79 patients. J Int Med Res 45:706–713. CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Bardin F, Chevallier O, Bertaut A, Delorme E, Moulin M, Pottecher P, Di Marco L, Gehin S, Mourey E, Cormier L, Mousson C, Midulla M, Loffroy R (2017) Selective arterial embolization of symptomatic and asymptomatic renal angiomyolipomas: a retrospective study of safety, outcomes and tumor size reduction. Quant Imaging Med Surg 7:8–23. CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Lee SY, Hsu HH, Chen YC, Huang CC, Wong YC, Wang LJ, Chuang CK, Yang CW (2009) Evaluation of renal function of angiomyolipoma patients after selective transcatheter arterial embolization. Am J Med Sci 337:103–108. CrossRefPubMedGoogle Scholar
  17. 17.
    Williams JM, Racadio JM, Johnson ND, Donnelly LF, Bissler JJ (2006) Embolization of renal angiomyolipomata in patients with tuberous sclerosis complex. Am J Kidney Dis 47:95–102. CrossRefPubMedGoogle Scholar
  18. 18.
    Planche O, Correas JM, Mader B, Joly D, Mejean A, Helenon O (2011) Prophylactic embolization of renal angiomyolipomas: evaluation of therapeutic response using CT 3D volume calculation and density histograms. J Vasc Interv Radiol 22:1388–1395. CrossRefPubMedGoogle Scholar
  19. 19.
    Villalta JD, Sorensen MD, Durack JC, Kerlan RK, Stoller ML (2011) Selective arterial embolization of angiomyolipomas: a comparison of smaller and larger embolic agents. J Urol 186:921–927. CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  1. 1.Department of Interventional Radiology and Vascular SurgeryPeking University First HospitalBeijingPeople’s Republic of China

Personalised recommendations